药物临床试验登记与信息公示平台数据显示,上海复宏汉霖生物技术股份有限公司/上海复宏汉霖生物医药有限公司的一项评估HLX43 (抗PD - L1的ADC)在晚期胰腺癌受试者中有效性和安全性的II期临床研究已启动。临床试验登记号为CTR20254319,首次公示信息日期为2025年11月14日。该药物剂型为粉针剂,规格为100mg/瓶/盒,用法用量为2.5mg/kg,Q3W;3.0mg/kg,Q3W。...
Source Link药物临床试验登记与信息公示平台数据显示,上海复宏汉霖生物技术股份有限公司/上海复宏汉霖生物医药有限公司的一项评估HLX43 (抗PD - L1的ADC)在晚期胰腺癌受试者中有效性和安全性的II期临床研究已启动。临床试验登记号为CTR20254319,首次公示信息日期为2025年11月14日。该药物剂型为粉针剂,规格为100mg/瓶/盒,用法用量为2.5mg/kg,Q3W;3.0mg/kg,Q3W。...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.